Compare Atlassian Corporation PLC (TEAM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs GeneDx Holdings Corp — how do they compare? Atlassian Corporation PLC trades at $206.64 (market cap $51.53B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Atlassian Corporation PLC is far larger — about 25.5× GeneDx Holdings Corp's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Atlassian Corporation PLC for 65 Days and GeneDx Holdings Corp for 19 Days on average.
| TEAM | WGS | |
|---|---|---|
Market Cap | $51.53B | $2.02B |
Volume | 2,904,511 | 734,640 |
Sector | Technology | Health |
52-Week High | $203.57 | $167.51 |
52-Week Low | $57.15 | $34.51 |
Typical Hold Time | 65 Days | 19 Days |
Enterprise Value | $51.52B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $205.09, up 4.81% today, showing strong momentum with three consecutive quarterly earnings beats. The stock maintains a bullish technical signal with moving averages supporting upward momentum, though RSI suggests potential overbought conditions. Revenue growth remains robust at $5.22B for 2025, with improving margins despite negative net income. Recent news highlights accelerating cloud migration and AI adoption driving investor optimism.
Outlook remains positive with 69.77% analyst buy ratings and a $140B addressable market growing at 14% annually. Key risks include persistent negative profitability, high valuation multiples, and competitive pressures. The stock trades above consensus price target of $191.16, suggesting near-term consolidation potential despite long-term growth catalysts from AI and cloud expansion.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
